How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).

R Dillon, N Potter, S Freeman, N Russell

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)
    Original languageEnglish
    JournalBritish Journal of Haematology
    DOIs
    Publication statusE-pub ahead of print - Oct 2020

    Keywords

    • AML
    • NPM1 mutations
    • molecular MRD

    ASJC Scopus subject areas

    • Hematology

    Cite this